Abstract YO18
Case summary
Case Details - A 47-year-old female, a known case of multicentric Glioblastoma multiforme (grade four) who had received concurrent chemoradiotherapy followed by palliative Temozolomide on tapering doses of Levetiracetam and had been commenced on Phenytoin presented (during the peak of the second wave of Pandemic) with complaints of new-onset maculopapular lesions involving legs, arms, and lower back. She subsequently developed a worsening Rash with the development of vesico-bullous lesions, oral mucosal lesions, acral involvement, and systemic symptoms (Fever) 2 days later. Arrangements were made to obtain a Tele Dermatology consult (from a Private setting) following which a diagnosis of SJS TENS Overlap was made. A consult with the Medical Oncology department was sought in order to provide ICU admission which was refused. She was subsequently admitted under Palliative Medicine after obtaining high-risk consent. Her lesions regressed with supportive management comprising Cyclosporin, and intravenous antibiotics, however, her general condition deteriorated. She was discharged as she had expressed a wish to meet her mother (at home). However, she was unable to obtain a fitness for Air travel. She was re-admitted and re-started on supportive treatment (symptom-directed medications via intravenous route). A subcutaneous line was inserted in the anterior chest wall and pre-filled syringes containing essential pain medication, anti-seizure medication (sc bolus levetiracetam), and dexamethasone for three days were provided to the Patient’s husband who had volunteered to take her back home via Train.
Discussion - Important Issues included Logistical - Lack of infrastructure, Medical - use of boluses of subcutaneous medication at end of life (without syringe drivers).
Conclusion - Practical Issues related to Travel, Finances, and Continuity of care may assume more importance than Spirituality underlining the importance of formulating a comprehensive management plan most suited to the Patient and their Family members.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06